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Background: Fractional exhaled nitric oxide (FeNO) is a surrogate marker of eosinophilic airway inflammation and
good predictor of corticosteroid response.
Aim: To evaluate how FeNO is being used to guide primary care asthma management in the United Kingdom (UK)
with a view to devising practical algorithms for the use of FeNO in the diagnosis of steroid-responsive disease and
to guide on-going asthma management.
Methods: Eligible patients (n = 678) were those in the Optimum Patient Care Research Database (OPCRD) aged
4–80 years who, at an index date, had their first FeNO assessment via NIOX MINO® or Flex®. Eligible practices were
those using FeNO measurement in at least ten patients during the study period. Patients were characterized over
a one-year baseline period immediately before the index date. Outcomes were evaluated in the year immediately
following index date for two patient cohorts: (i) those in whom FeNO measurement was being used to identify
steroid-responsive disease and (ii) those in whom FeNO monitoring was being used to guide on-going asthma
management. Outcomes for cohort (i) were incidence of new ICS initiation at, or within the one-month following,
their first FeNO measurement, and ICS dose during the outcome year. Outcomes for cohort (ii) were adherence,
change in adherence (from baseline) and ICS dose.
Outcomes: In cohort (i) (n = 304) the higher the FeNO category, the higher the percentage of patients that initiated
ICS at, or in the one month immediately following, their first FeNO measurement: 82%, 46% and 26% of patients with
high, intermediate and low FeNO, respectively. In cohort (ii) (n = 374) high FeNO levels were associated with poorer
baseline adherence (p = 0.005) but greater improvement in adherence in the outcome year (p = 0.017). Across both
cohorts, patients with high FeNO levels were associated with significantly higher ICS dosing (p < 0.001).
Conclusions: In the UK, FeNO is being used in primary practice to guide ICS initiation and dosing decisions and to
identify poor ICS adherence. Simple algorithms to guide clinicians in the practical use of FeNO could improved
diagnostic accuracy and better tailored asthma regimens.
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Inhaled anti-inflammatory (corticosteroid, ICS) therapy
is the cornerstone of asthma management with the ul-
timate goal of maintaining control of the clinical mani-
festations of the disease for prolonged periods [1].
Initiation of maintenance therapy as either low-dose ICS
or as a leukotriene receptor antagonist (LTRA) is recom-
mended for patients who remain symptomatic despite
as-needed short-acting bronchodilator therapy [2,3]. In
patients who remain sub-optimally controlled on low-
dose ICS, an increase in ICS dose (to medium- or high-
dose), or the addition of a long-acting bronchodilator
(LABA) or LTRA is recommended. For those who con-
tinue to be uncontrolled, further management options
include higher doses of ICS, maintenance oral cortico-
steroids and anti-IgE therapy [2,3].
Achieving optimum asthma control requires an under-
standing of the nature and extent of the airway inflamma-
tion present. In the Gaining Optimum Asthma controL
(GOAL) study, for example, over 30% of patients failed to
achieve totally controlled asthma despite receiving max-
imum doses of fluticasone propionate. While drug delivery
and/or treatment adherence may have played a part in
their failure to achieve control, it may also have been par-
tially attributable to the presence of steroid unresponsive
asthma in these patients [4,5].
ICS dosing decisions (starting dose and subsequent
dose adjustments) are typically symptom-driven and reli-
ant on patient or carer/parental reports [6]. Yet respira-
tory symptoms can be non-specific and are not necessarily
related to the extent or severity of the inflammation
present [7]. Moreover, lung function and symptom scores
have only a modest correlation with airway inflammation
[8]. Indeed, although eosinophilic airway inflammation
has been shown to be closely linked to steroid response
[9-14], it has only a weak correlation to airway dysfunction
and to symptoms [15,16]. Thus, a standard clinical assess-
ment that relies on symptom assessment and simple lung-
function tests alone provides limited information about
the presence, or absence, of airway inflammation, or the
extent to which a patient is at risk of future asthma
exacerbations.
Fractional exhaled nitric oxide
Approximately 50% of asthma cases are attributable to
eosinophilic airway inflammation [17-19]. Eosinophilic
airway inflammation results from the activation of mast
cells and antigen-specific Th2 cells resulting in the pro-
duction of cytokines and up-regulation of epithelial
inducible nitric oxide (NO) [2]. The fraction of NO ex-
haled (FeNO) is elevated in patients with eosinophilic
airway inflammation, yet generally remains low in pa-
tients with non-eosinophilic asthma [14]. FeNO has
been shown to be closely correlated to findings usinginduced sputum and more invasive measures of airway
inflammation (e.g. as bronchial biopsy). Thus, as a surro-
gate marker of eosinophilic airway inflammation and a
good predictor of corticosteroid response (both positive
and negative), FeNO has been proposed as a useful bio-
marker in patients with asthma [20-23].
The role of FeNO as a diagnostic and decision-support
tool is relatively well documented [24-26]. Indeed, in
2011 the American Thoracic Society (ATS) published a
comprehensive review of the literature in a clinical prac-
tice guideline that endorsed (strong recommendation;
weak evidence) the use of FeNO as a quantitative, non-
invasive, simple, and safe method of measuring airway
inflammation and provides clinical guidance on its use
for the diagnosis and management of asthma [24].
Yet despite the body of evidence underpinning the po-
tential uses of FeNO, its uptake within primary care re-
mains limited. This is, in part, due to a lack of clear,
practical guidance on its appropriate use in routine
asthma care and how it can be best utilized to aid diag-
nosis and support decision making with respect to ICS
dose optimization and the need for non-ICS therapies.
Against this backdrop, we designed a study to identify
patterns of use of FeNO assessment in routine primary
care in the United Kingdom (UK) and the effects of this
assessment on clinical parameters and physician and pa-
tient behaviour with a view to informing algorithms for
the use of FeNO in primary care practice.
Methods
Data sources and patients
This observational study analyzed clinical data from the
Optimum Patient Care Research Database (OPCRD).
The OPCRD is a UK respiratory dataset containing
anonymized, longitudinal, research-quality clinical re-
cords and patient-reported outcome data from practices
that subscribe to the Optimum Patient Care (OPC) re-
spiratory review service. At the time of the study, the
OPCRD included 341,000 patients at 176 practices [27].
The OPCRD has been approved by Trent Multi Centre
Research Ethics Committee for clinical research use, and
the study protocol was approved by ADEPT (Anonymised
Data Ethics Protocols and Transparency Committee), the
OPCRD’s independent scientific advisory committee.
Eligible patients were those aged 4–80 years who, at an
index date, had their first FeNO measurement via NIOX
MINO® or Flex®. Patients had to be managed at practices
routinely measuring FeNO, defined as those that mea-
sured FeNO in at least ten patients over the study period.
All eligible patients had to have at least one (baseline) year
of continuous practice data before the index date, and one
complete (outcome) year of data after the index.
During baseline, all patients were characterised in
terms of demography, clinical management, exacerbation
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controlled in baseline if they used little symptom relief
medication (average SABA use of ≤200 μg daily) and
high risk if they had multiple (i.e. at least two) exacer-
bations over the baseline year. Normal, intermediate and
high FeNO levels were categorised as: low/normal: <25 ppb
(adults), <20 ppb (children); intermediate: 25–50 ppb
(adults), 20–35 ppb (children); or high: >50 ppb (adults),
>35 ppb (children) (see Table 1).
The implications of FeNO measurement and monitor-
ing were evaluated in two patient cohorts: (i) those in
whom FeNO measurement was being used to identify
possible steroid-responsive disease (i.e. in patients not
receiving ICS therapy during the baseline year) and (ii)
those in whom FeNO monitoring was being use to sup-
port clinical management of asthma (i.e. in patients who
received at least one prescription for ICS therapy during
the baseline year).Study endpoints
In patients in whom FeNO measurement was being used
to help identify possible steroid-responsive disease, the
percentage of patients initiating ICS at, or in the one
month immediately following their first FeNO measure-
ment was evaluated and split by FeNO category (low/
normal, intermediate, high) to explore the effect of
FeNO measurement on physician prescribing behaviour.
In the cohort of patients in whom FeNO monitoring
was being use to support asthma clinical management,
the association between adherence to ICS in the baseline
and outcome years (and change in ICS adherence be-
tween baseline and outcome) was evaluated, and split
by FeNO category, to explore the effect of FeNO level
on subsequent patient behaviour. Adherence was
assessed in terms of medication possession ratio (MPR,
defined as number of days’ supply of therapy/number
of days in the total prescribing period × 100%).
Across both cohorts, the association between FeNO
level and prescribed ICS dose was evaluated, with ICS
dose being a marker of FeNO’s effect on physician
prescribing behaviour.Table 1 Categorisation of FeNO level - low/normal;
intermediate; high by age (i.e. adults and children)
Adults/Adolescents
(Ages 12 and older)
Children
(Ages 4–11)
Low/normal (ppb) <25 <20
Intermediate (ppb) ≥25 and ≤50 ≥20 and ≤35
High (ppb) >50 >35
Normal FeNO level = <25 ppb/<20 ppb in patients age ≥12/< 12 years.
Intermediate FeNO level = 25–50 ppb/20-35 ppb in patients age ≥12/< 12 years.
High FeNO level = >50 ppb/>35 ppb in patients age ≥12/< 12 years.Statistical analyses
Analyses were conducted using SPSS version 18 (SPSS
Statistics, IBM, Somers, NY, USA), SAS version 9.2 (SAS
Institute, Marlow, Buckinghamshire, UK), and Microsoft
Office Excel 2007 (Microsoft, Bellevue, WA, USA). Sta-
tistical significance was defined as p < 0.05. Descriptive
analysis was used to investigate patterns of FeNO assess-
ment and the effect on physician prescribing. Plots and
statistical tests were used to explore the relationships
between FeNO levels and ICS consumption/patient ad-
herence using, namely Kruskal Wallis Test for variables
measured on the interval/ratio scale and Chi Square Test
for categorical variables.
Results
All patients
A total of 678 eligible patients were identified in the
database. The median (interquartile range) age of the
study population was 46 (26–60) years, 46% of patients
were male, 45% had comorbid rhinitis and 6% of patients
were current smokers. During baseline, 7% of the pa-
tients experienced multiple exacerbations, classifying
them as high risk (12% had 1 exacerbation and 81% had
no exacerbations during baseline) (see Table 2).
Precise FeNO values were available for 73% of the
population (n = 497) of whom, 56% had low/normal
FeNO levels, 27% had intermediate levels and 17% had
high levels. Across all patients, the higher the FeNO
category, the higher the median prescribed ICS dose in
the outcome year – a sign that FeNO measurement/
monitoring was informing rationale prescribing deci-
sions (see Table 3).
Identifying possible steroid-responsive disease
FeNO measurement was being used to help identify pos-
sible steroid-responsive disease in 304 patients. ICS was
initiated within one month of the index date (i.e. first
FeNO measurement) in 82% of patients with high FeNO
levels, 46% of those with intermediate FeNO levels and
approximately one quarter (26%) of patients with low/
normal FeNO (see Figure 1).
Monitoring FeNO as part of asthma clinical management
Of the 678 total patient population, 374 had received at
least one prescription for ICS (alone or in combination
with other asthma therapy) prior to their first FeNO
measurement (see Figure 1). There was no apparent re-
lationship between baseline asthma control status or ex-
acerbation rate and initial FeNO level, although only a
relatively small percentage (16%) of patients had high
FeNO at time of first assessment (see Figure 1). How-
ever, there was a significant association between baseline
adherence and FeNO level at index date, with higher
initial FeNO levels associated with lower baseline
Table 2 Summary baseline characteristics of the eligible
study population
Baseline characteristics Study
population
n = 678
Sex: male n (%) 313 (46.2)
Age: median (IQR) 46 (26, 60)
BMI, median (IQR) 26.0 (22.9, 30.6)
Rhinitis diagnosis
or therapy, n (%)
305 (45.0)
Smoking status, n (%) Current Smoker 40 (5.9)
Ex-smoker 145 (21.4)
Non-smoker 477 (70.4)
Exacerbations, n (%) 0 551 (81.3)
1 83 (12.2)
≥2 44 (6.5)
SABA dose (mcg), n (%) 1-100 121 (17.8)
101-200 132 (19.5)
201-400 94 (13.9)
401+ 47 (6.9)
Average ICS Daily dose,
(mcg) BDP-equivalent
dose, n (%)
None 304 (44.8)
1-100 67 (9.9)
101-200 106 (15.6)
201-400 101 (14.9)
401+ 100 (14.7)
Asthma therapy, n (%) None 193 (28.5)
SABA 101 (14.9)
±SABA
LTRA 8 (1.2%)
ICS 182 (26.8)
ICS + LABA 136 (20.1)
ICS + LAMA 1 (0.1)
±SAMA ICS + LABA + LAMA 5 (0.7)
ICS + LTRA 8 (1.2)
ICS + LABA + LTRA 42 (6.2)
Other 2 (0.3)
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levels were also associated with greater improvement
in adherence in the following year – a proxy marker
of patient reaction to FeNO monitoring (p = 0.017, see
Figure 3).Table 3 Median ICS dose increase following initial FeNO read
Initial FeNO
Low Intermedia
n (%) 276 (55.5) 135 (27.2)
Median (IQR) ICS dose increase (μg) 0 (0–261) 152 (0–382Discussion
The results of this real-life evaluation of FeNO monito-
ring in UK primary care practice suggest FeNO is being
used (by the subgroup of practices included in the study)
as a complementary diagnostic tool to aid diagnosis in
patients in whom traditional assessment tools may have
been inconclusive. It appears to be being used to guide
decisions around ICS initiation or step up.
While FeNO can provide useful information about the
nature and presence (or absence) of eosinophilic airway
inflammation and about the likelihood (or not) of ICS
responsiveness, it can also be used to identify poor ad-
herence. These data suggest that a high FeNO level ap-
pears to drive improved ICS adherence in routine care.
Using FeNO in this way has the potential to optimize
existing therapy and minimize inappropriate use of ICS
in patients unlikely to respond.
This real-life study adds to a rather limited evidence
base on the role of FeNO monitoring in asthma manage-
ment. At one point, the combined findings of a Cochrane
systematic review of FeNO-based asthma management
and a meta-analysis of studies evaluating the role of FeNO
or sputum eosinophils in asthma management of patients
concluded FeNO-guided asthma management could not
be recommended (for adults or children) and that further
studies were needed [28,29]. This conclusion was subse-
quently challenged on the basis that both the Cochrane
review and the meta-analysis used the number of partici-
pants who had asthma exacerbations during follow-up as
the primary endpoint, which does not take into conside-
ration the fact that some patients may have multiple exac-
erbations during the course of a study. Indeed, the
National Institute for Health (NIH) considers time to first
asthma exacerbation and/or asthma exacerbation rates to
be the most meaningful outcomes for assessing asthma
exacerbations [30]. A re-analysis of the data from the
Cochrane review and the meta-analysis [28-30] using
asthma exacerbation rates as the endpoint (and using the
standard Cochrane meta-analysis approach) found the
rate of exacerbations was significantly lower in patients
receiving a FeNO-based asthma management strategy,
in both adults and children [31-35].
Pooling the evidence from the existing literature and
the results of this real-life study together with our own
experience of using FeNO in clinical practice, we have
devised two clinical practice algorithms to aid primary
care practitioners in the practical use of FeNOing, split by FeNO category
reading Total p-value
(Kruskal Wallis)te High
86 (17.3) 497 (100.0) <0.001
) 219 (109–429) -
Figure 1 Algorithm by showing how FeNO was used in 678 patients from the OPCRD. Patients were aged ≥4 years with at least one year’s
continuous patient records prior to their first FeNO reading.
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Algorithm”, which aims to provide guidance on the use
of FeNO at the time of initial asthma diagnosis where
traditional tools are inadequate (Figure 4). The second is
an “On-going Monitoring and Decision Support Algo-
rithm” to guide use of FeNO within longer-term asthma
management and to inform prescribing decisions post
diagnosis (Figure 5).
Initial evaluation algorithms
The Initial Evaluation Algorithms build on an under-
standing that FeNO cannot be used to diagnose asthma
(as asthma is defined by symptoms and variable airflowResult of Initial FeNO Reading
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Figure 2 Adherence to ICS during baseline year, split by FeNO
category at time of initial FeNO measurement. Legend: n = 260:
Patients from OPCRD who were prescribed an ICS in year prior to
1st FeNO reading AND a recorded FeNO reading.obstruction), but that it can be used to indicate elevated
FeNO levels, the presence of eosinophilic airway inflam-
mation and likely steroid response. Indeed, it can be a
valuable complementary diagnostic tool and guide to
therapeutic decision-making in patients with non-specific
respiratory symptoms that are difficult to diagnose using
conventional tools [9,10,24,25]. Where further investiga-
tions are felt necessary, we propose its inclusion in theFigure 3 Change in ICS adherence in the year following initial
FeNO measurement, split by FeNO category. Legend: n = 226:
Patients from OPCRD who were prescribed ICS in the year prior to
and post the 1st FeNO reading and in whom a specific FeNO value
was recorded at time of first measurement.
Routine Assessments
• Symptom reports
• Lung function measurements
• Patient reports
• Unlikely to have 
asthma
• Unlikely to have 
ICS-responsive 
• Consider other 
diagnoses
• Consider other 
diagnoses
• Consider 1-month trial 
of ICS therapy if there 
is a strong clinical 
suspicion of asthma 
If no symptom 
improvement after ICS 
trial, consider:
• Other diagnoses
• Specialist referral
Follow-up per routine
(see Figure 2:  
“On-going management 
of established asthma”)
Introduce FeNO 
assessment
Low FeNO levels
Adults: <25ppb
Children <20ppb
Intermediate FeNO levels
Adults: 25–50ppb
Children 20–35ppb
High FeNO levels
Adults: >50ppb
Children >35ppb
Normal lung 
function
Normal lung 
function
Normal lung 
function
Abnormal lung 
function
Abnormal lung 
function
Abnormal lung 
function
• Use clinical judgement
• Consider 1-month trial of ICS
• Consider other diagnoses
If no clinical improvement 
after ICS trial
• Optimise therapy: 
evaluate inhaler  
technique, adherence and 
minimise triggers
• Consider other diagnoses
• Consider specialist 
referral
If clinical improvement 
after ICS trial:
• Continue with ICS
• Follow-up per 
routine
• High likelihood of asthma
• High likelihood of ICS-
• Initiate ICS treatment
Figure 4 Clinical pathway for incorporating FeNO measurement at the time of initial evaluation of non-specific respiratory symptoms
and diagnosis of steroid-responsive disease.
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tion testing. Our recommendations on how FeNO can be
used at the time of initial evaluation of non-specific
respiratory symptoms are summarized in Figure 4.
Low FeNO levels
The presence of low FeNO levels in untreated patients
with normal spirometry can help to rule out asthma (see
Figure 4). Alternatively, low FeNO levels may indicate
the possibility of non-eosinophilic asthma (or a diagnosis
other than asthma). In either case, the likelihood of
ICS-response is low and the likelihood of a diagnosis
other than asthma is high. In general, ICS is not indi-
cated in such patients, unless the clinical suspicion for
asthma remains high (e.g. abnormal lung function, bron-
chodilator response), in which case a maximum 1-month
trial of anti-inflammatory therapy could be an option before
alternative diagnoses or specialist referral are considered.
Intermediate FeNO levels
In isolation, the presence of intermediate FeNO levels in
untreated patients with normal or abnormal spirometry
does not confirm or exclude the presence of asthma.FeNO levels in the intermediate range, particularly when
accompanied by evidence of airway obstruction, may in-
dicate the possibility of eosinophilic asthma. However,
FeNO levels in this range may also be consistent with
non-eosinophilic asthma or a diagnosis other than asthma.
If FeNO levels are found to be in the intermediate range
and no definitive alternative diagnosis is evident, we rec-
ommend a 1-month trial of ICS (see Figure 4). If the pa-
tient responds to therapy (symptoms, lung function and/
or normalization of FeNO), ICS should be continued and
the patient monitored as per routine (including continued
FeNO monitoring to help guide on-going management).
Where no improvement in FeNO and no objective
clinical improvement has occurred following a thera-
peutic trial of ICS, we strongly recommend that alterna-
tive diagnoses or specialist referral be considered.
High FeNO levels
High FeNO levels (with or without normal spirometry)
indicate that eosinophilic airway inflammation is present
and that the likelihood of ICS response is high. Con-
sequently initiation of ICS therapy is recommended.
However, specialist referral may still be necessary for
Routine Assessments
• Symptom reports
• Exacerbation history
• Lung function measurements
• Patient reports
Low FeNO levels
Adults: <25ppb
Children <20ppb
Intermediate FeNO levels
Adults: 25–50ppb
Children 20–35ppb
High FeNO levels
Adults: >50ppb
Children >35ppb
On-going management of established asthma
Symptomatic Symptomatic SymptomaticAsymptomatic Asymptomatic Asymptomatic
• Consider other 
diagnoses
• Consider adding a 
non-ICS therapy
• Evaluate ICS 
adherence 
  (including the  
possibility of a recent  
improvement in  
adherence following an 
asthma-related event) 
• Optimise existing 
therapy
– Evaluate inhaler    
   technique
– Evaluate ICS 
adhernece   
• Consider ICS dose 
increase or small 
molecule ICS
• Consider also adding 
non-ICS therapy 
to optimise 
 
control (e.g. LTRA)
• Optimise existing 
therapy
– Evaluate inhaler    
   technique
– Evaluate ICS 
   adherence
• Consider ICS dose 
increase or small 
molecule ICS
• Consider also 
adding non-ICS 
therapy to optimise 
 
control (e.g. LTRA)
• Consider ICS dose 
reduction
• Consider ICS dose 
withdrawal if on 
low-dose ICS
• Optimise existing 
therapy
– Evaluate inhaler    
   technique
– Evaluate ICS 
   adherence
• ICS dosing:
– Initially: no change
– If stable FeNO 
for 3–6 months: 
consider step-down 
with follow-up within  
4 weeks
• Optimise existing 
therapy
– Evaluate inhaler    
   technique
– Evaluate ICS adherence
• Consider:
– Continuing on existing 
ICS dose
– Establishing patient’s 
baseline, i.e. a trial of 
increased ICS or short 
course of oral steroids. 
If high FeNO baseline is 
 (and disease 
remains stable) consider 
cautious step-down, with 
follow-up within 4 weeks
Follow-up within 
4 weeks to ensure: 
•  No increase in 
FeNO level
•  No loss of asthma 
control
Introduce FeNO 
assessment
Figure 5 Clinical pathway for incorporating FeNO monitoring into on-going asthma management.
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and high FeNO levels if they do not respond to treat-
ment with an ICS (see Figure 4). This scenario is dis-
cussed further below in the On-going monitoring section.
In such patients it is particularly important to consider
factors such as compliance with therapy, trigger factors,
and inhaler technique before concluding a patient has
not responded to therapy or that they need additional
therapy.
On-going monitoring and decision support algorithm
FeNO monitoring should be used in conjunction with
structured assessments (validated assessment tools, lung
function measurements, exacerbation history and patient
reports) to provide supplementary information about a
patient’s disease state and to help tailor asthma therapy
appropriately. FeNO can be particularly useful when
trying to identify patients who may be at increased risk
of asthma exacerbations [36-38]; those who are non-
compliant to corticosteroid therapy [39-41]; those who
may be suitable for a change in therapy (step up or step
down) [40,41], and when trying to assess whether
corticosteroid-responsive airway inflammation has beencontrolled [42]. In addition, serial FeNO measurements
can be used to monitor therapeutic response to (and ad-
herence to) current therapy and to assess possible
changes in allergen exposure in patients with known
atopic inflammation.
Our recommendations on how FeNO can be used as a
decision-support tool once a diagnosis of asthma has
been established are summarised in Figure 5.
Low FeNO levels
In the case of maintenance ICS patients who have low
FeNO levels yet remain symptomatic, care must be
taken to understand the reason for the persistence of
symptoms. Alternative diagnoses and/or the presence of
comorbidities (e.g. reflux, dysfunctional breathing) should
be explored. Patients’ smoking habits should also be dis-
cussed. Not only can smoking reduce FeNO levels (pos-
sibly an early indicator of smoking’s impact on the lungs),
but it can also drive management with higher ICS doses,
both of which can increase the chance of a “false low”
FeNO reading. Chronically reduced levels of FeNO have
been demonstrated due to habitual smoking, but acute ef-
fects have also been shown immediately after cigarette
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ished by smoking, the depressant effect is not absolute
and smokers with asthma can still have a raised FeNO
[47]. To minimize the recording of falsely low FeNO read-
ing, patients should be advised not to smoke in the hour
before measurements, and short- and long-term active
and passive smoking history should be recorded [48].
In patients with low FeNO levels in whom the diagno-
sis of asthma appears valid (e.g. confirmatory spirometry
and bronchodilator response) increasing ICS is unlikely
to result in an improvement in symptoms or other
asthma outcomes. Instead, addition of a non-ICS therapy
(e.g. an LTRA or LABA) should be considered. Also, as
FeNO is highly ICS responsive (and low FeNO levels
could indicate good adherence to ICS therapy) it is worth
exploring whether there has been any recent change in a
patient’s usual adherence pattern (e.g. an improvement in
adherence in response to a recent exacerbation) that may
have led to a short-term reduction in FeNO levels.
Where patients are asymptomatic, have low FeNO
levels and have stable, well-controlled disease, a reduc-
tion in ICS dose (or ICS cessation if existing dose is low)
should be considered. The chances of loss of control are
much lower in patients with a low FeNO. Those selected
for step-down should be followed-up (involving appro-
priate clinical investigations, including peak flow moni-
toring if appropriate) within 4 weeks, especially where
the step-down is to low-dose ICS or where the ICS is be-
ing discontinued. If FeNO levels rise during the follow-
up period, it may be a precursor to future loss of control
and indicates the need to restart or increase ICS therapy.
The 4-week follow-up recommendation is based on data
from studies in both children and adults demonstrating
that a 4-week period is adequate to identify individuals
who are likely to experience an increase/decrease in their
level of asthma control (based on increased/decreased
FeNO levels) and be at increased/decreased risk of ha-
ving an exacerbation [49-51]. A challenging group of
patients to manage are those on high dose ICS (or high
dose ICS containing regimens) who have some symp-
toms, but may not be particularly benefiting from high
dose ICS. FeNO may be especially useful in guiding and
reviewing step-down decisions in this group, but real-life
research is required to evaluate the true value of FeNO
in this particular clinical setting.
Intermediate or high FeNO levels
We recommend no initial changes to existing ICS the-
rapy, in asymptomatic patients with intermediate FeNO
levels. Such patients should be followed for an additional
3–6 months and if they remain asymptomatic and their
FeNO levels remain stable, a reduction in ICS dose can
be considered with a follow-up in 4 weeks including an
evaluation of symptom control, lung function and FeNO.However, it is important to recognize that in apparently
stable patients, a rise in FeNO may indicate the possibi-
lity of a future loss of control. Thus, patients who have
had an increase in FeNO levels to the intermediate zone,
even in the absence of symptoms, should be followed
more closely as they may be at risk of reduced asthma
control. In all cases, medication adherence, trigger fac-
tors and inhaler technique should be carefully assessed.
On occasion, a patient with a high FeNO level and
otherwise apparently well-controlled asthma and no his-
tory of frequent exacerbations will be encountered. The
high but stable FeNO level may represent the “normal
baseline” for some patients, but a trial of increased ICS
(or even a 10–14 day course of oral corticosteroids) to
definitively establish their “normal” baseline may be ap-
propriate. Once a patient’s baseline has been established,
and if they remain asymptomatic with stable FeNO
levels, a reduction in ICS dose can be cautiously consid-
ered with follow-up in 4 weeks.
The presence of elevated (intermediate or high) FeNO
levels in patients who remain symptomatic despite main-
tenance ICS therapy indicates sub-optimal control. For
such patients, it is imperative to assess medication ad-
herence, trigger factors and inhaler technique before any
changes in treatment are considered. Where the patient
remains symptomatic with elevated FeNO levels despite
an evaluation and optimization of these factors, improved
control may be possible by increasing the ICS dose or by
addition of LTRA to improve anti-inflammatory manage-
ment. Or specialist referral should be considered.
Conclusions
In conclusion, FeNO monitoring should be viewed as a
complementary assessment and monitoring tool when
traditional assessment techniques prove inadequate or
inconclusive. It can offer added advantages for clinicians
(and patients) in terms of: (1) detecting the presence of
eosinophilic airway inflammation, (2) determining the
likelihood of ICS responsive (and lack thereof), (3) moni-
toring of airway inflammation to determine the potential
need for a corticosteroid, and (4) unmasking (otherwise
unsuspected) non-adherence to corticosteroid therapy.
Using FeNO to guide asthma management may not
only benefit patients and reduce pressures on healthcare
professionals, but could also reduce asthma-related
healthcare costs [52-54]. FeNO-related cost savings could
be realized through a variety of mechanisms, such as: re-
ducing the use of inappropriately high doses of ICS (where
ICS response has plateaued, or in patients who are stable
and eligible for ICS dose reduction or cessation), and by
reducing the cost of managing the effects of sub-optimal
control (e.g. hospitalizations, exacerbations) in patients in
whom guided step-up, or add-on therapy may be more
beneficial. A UK cost-effectiveness study evaluated the
Price et al. Clinical and Translational Allergy 2013, 3:37 Page 9 of 10
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diagnostic and monitoring tools. For diagnosis, FeNO
costs were compared against those for lung function and
reversibility testing, bronchial provocation and sputum
eosinophil count. For asthma management, the impact
of FeNO monitoring on asthma control over one year
(including ICS use, exacerbations and hospitalizations)
was compared to symptoms and lung function (as in
standard care). FeNO was measured using a hand-held
monitor (NIOX MINO) at a reimbursement price of
23 pound sterling (£). The study found that an asthma
diagnosis using FeNO cost £43 less per patient as com-
pared with standard diagnostic tests. Asthma management
using FeNO measurement (instead of lung function test-
ing) resulted in annual cost-savings of £341 pound sterling
for patients with mild to severe asthma and savings of
£554 pound sterling for those with moderate to severe
asthma [54]. While these data are of interest, further stu-
dies are required to explore the potential benefits and cost
implications of FeNO-guided asthma management across
a spectrum of asthma severities.
While some studies based in academic medical centres
have found that physician-based treatment decisions are
non-inferior to biomarker- or symptom-based ICS ad-
justments in mild-moderate asthma, [55] we believe that
FeNO monitoring (use as discussed in our proposed
clinical pathways) can assist primary care physicians who
are not experts in respiratory disease to achieve improved
diagnostic accuracy in patients with non-specific respira-
tory symptoms and to achieve more tailored and targeted
treatment regimens for on-going asthma management.
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